Related Experiment Video
Updated: Oct 30, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer
Myong Hak Ri1, Juan Ma2, Xuejun Jin2
1Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, 133002, Jilin Province, China; Faculty of Life Science, Kim Il Sung University, Pyongyang, Democratic People's Republic of Korea.
Ethnopharmacological Relevance:
The programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint is one of the most promising therapeutic targets for cancer immunotherapy, but several challenges remain in current anti-PD-1/PD-L1 therapy. Natural products, mainly derived from traditional medicine, could improve and expand anti-PD-1/PD-L1 therapy because of their advantages such as large diversity and multi-target effects.
Aim Of The Study:
This review summarize natural products, raw extracts, and traditional medicines with pharmacological effects associated with the PD-1/PD-L1 axis, particularly PD-L1.
Materials And Methods:
Electronic literature databases, including Web of Science, PubMed, and ScienceDirect, and online drugs and chemicals databases, including DrugBank, ZINC, PubChem, STITCH, and CTD, were searched without date limitation by February 2021. 'Natural product or herb or herbal plant or traditional medicine' and 'PD-L1' and 'Cancer immunotherapy' were used as the search keywords. Among 112 articles identified in database searching, 54 articles are full text articles, reporting in silico, in vitro, in vivo and clinical trials. 68 articles included are review articles and grey literature such as thesis and congress abstracts.
Results:
Several natural products and traditional medicines have exhibited diverse and multi-functional effects including direct blockade of PD-1/PD-L1 interactions, modulation of PD-L1 expression, and cooperation with PD-1/PD-L1 inhibitors.
Conclusion:
Natural products and traditional medicines can facilitate the development of more effective and acceptable diverse strategies for anti-PD-1/PD-L1 therapy, but further exploration of natural products and pharmaceutical techniques is required.
Insights
Natural products and traditional medicines offer diverse strategies to enhance cancer immunotherapy targeting the PD-1/PD-L1 axis. Further research is needed to optimize their use in combination with existing therapies.
Area of Science:
- Immunology
- Pharmacology
- Oncology
Background:
- The programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway is a key target in cancer immunotherapy.
- Current anti-PD-1/PD-L1 therapies face challenges, necessitating novel approaches.
- Natural products offer a diverse source of compounds with potential to augment anti-PD-1/PD-L1 therapy.
Purpose of the Study:
- To review natural products, extracts, and traditional medicines impacting the PD-1/PD-L1 axis.
- To focus on agents modulating PD-L1 expression and function in cancer.
Main Methods:
- Comprehensive literature search of electronic and chemical databases (Web of Science, PubMed, DrugBank, etc.) up to February 2021.
- Keywords included 'Natural product', 'PD-L1', and 'Cancer immunotherapy'.
- Analysis of 54 full-text articles reporting in silico, in vitro, in vivo, and clinical data, alongside 68 review articles and grey literature.
Main Results:
- Identified natural products and traditional medicines with diverse effects on the PD-1/PD-L1 axis.
- Observed mechanisms include direct blockade of PD-1/PD-L1 interaction and modulation of PD-L1 expression.
- These agents demonstrated potential for synergistic effects with existing PD-1/PD-L1 inhibitors.
Conclusions:
- Natural products and traditional medicines can support the development of novel anti-PD-1/PD-L1 therapeutic strategies.
- Further investigation into natural product-derived compounds and advanced pharmaceutical techniques is warranted.
- These approaches may lead to more effective and tolerable cancer immunotherapies.
More Related Videos
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...